Jeff Fairman - 30 Dec 2022 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
VP, Research
Signature
Jeff Fairman, by /s/ Ron A. Metzger, Attorney-in-Fact
Issuer symbol
PCVX
Transactions as of
30 Dec 2022
Net transactions value
$0
Form type
4
Filing time
04 Jan 2023, 15:33:18 UTC
Previous filing
28 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PCVX Common Stock 17,827 30 Dec 2022 Direct F1
holding PCVX Common Stock 286,227 30 Dec 2022 By Fairman Family Trust
holding PCVX Common Stock 50,000 30 Dec 2022 By AF 2020 Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (Right to Buy) Award $0 +15,000 $0.000000 15,000 30 Dec 2022 Common Stock 15,000 $47.95 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Jeff Fairman is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Includes 684 shares acquired under the Issuer's Employee Stock Purchase Plan on November 17, 2022.
F2 1/48 of shares subject to the option vest on January 30, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.